Scancell Holdings PLC develops cancer treatments using its ImmunoBody®, Moditope®, and AvidiMabTM technology platforms. The company focuses on creating therapies for various types of cancer and has multiple products in development. Its business model includes generating revenue through collaboration agreements and potential funding from investors.